BridgeBio Pharma (BBIO) vs Viatris (VTRS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Viatris (VTRS) has outperformed BridgeBio Pharma (BBIO) over the past year, gaining 72.5% versus a gain of 22.6%. Over five years, BBIO leads with a +38.6% price change compared with +29.9% for VTRS. Viatris is the larger company by market cap ($20.09 billion vs $13.00 billion), about 1.5 times the size, while BridgeBio Pharma is growing revenue faster (+126.3% vs -3.0%).
On valuation, Viatris trades at a lower forward P/E (6.5x vs 2420.8x for BridgeBio Pharma). Viatris pays a dividend yielding 2.74%, while BridgeBio Pharma does not currently pay one. Viatris converts more of its revenue into profit, with a net margin of -24.6% versus -146.0%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BBIO | VTRS |
|---|---|---|
| Share price | $66.50 | $17.49 |
| Market cap | $13.00B | $20.09B |
| 1-day change | -0.69% | -0.29% |
| YTD return | -13.06% | +40.48% |
| 1-year return | +22.65% | +72.49% |
| 5-year return | +38.60% | +29.94% |
| Forward P/E | — | 6.54 |
| EPS (TTM) | $-3.53 | $-0.36 |
| Dividend yield | 0.00% | 2.74% |
| Annual dividend | $0.00 | $0.48 |
| Revenue (latest FY) | $502.08M | $14.30B |
| Revenue growth (YoY) | +126.26% | -2.98% |
| Net income (latest FY) | $-732.94M | $-3.51B |
| Gross margin | 95.82% | 35.06% |
| Operating margin | -104.25% | -18.62% |
| Net margin | -145.98% | -24.58% |
| 52-week high | $93.42 | $18.43 |
| 52-week low | $52.75 | $9.69 |
| Distance from 52-week high | -28.81% | -5.10% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +63.98% | +12.64% |
| Average volume | 2.76M | 9.20M |
| Shares outstanding | 195.49M | 1.15B |
| Employees | 999 | 30,000 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- VTRS has outperformed BBIO by 49.8 percentage points over the past year.
- Viatris offers a meaningfully higher dividend yield (2.74% vs 0.00%).
- Viatris is more profitable, keeping -24.6 cents of every revenue dollar as net income versus -146.0 cents for BridgeBio Pharma.
- BridgeBio Pharma grew revenue faster in its latest fiscal year (+126.26% vs -2.98%).
About BridgeBio Pharma
BBIO stock →BridgeBio Pharma, Inc., a biopharmaceutical company, discovers, develops, and delivers medicines for patients with genetic diseases. The company offers Attruby, a next-generation oral small molecule near-complete TTR stabilizer for the treatment of cardiomyopathy of wild-type or transthyretin-mediated amyloidosis (ATTR-CM); Fosdenopterin, an intravenous formulation of synthetic cyclic pyranopterin monophosphate for the treatment of molybdenum cofactor deficiency under the NULIBRY brand name; and low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 clinical stage or the treatment of children with achondroplasia and hypochondroplasia.
Health Care · Biotechnology: Pharmaceutical Preparations · 999 employees
About Viatris
VTRS stock →Viatris Inc., together with its subsidiaries, operates as a healthcare company in North America, Europe, China, Taiwan, Hong Kong, Japan, Australia, New Zealand, rest of Asia, Africa, Latin America, and the Middle East. It operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets.
Health Care · Biotechnology: Pharmaceutical Preparations · 30,000 employees
BBIO vs VTRS FAQ
Which is bigger, BridgeBio Pharma or Viatris?
Viatris (VTRS) is larger, with a market capitalization of $20.09B compared with $13.00B for BridgeBio Pharma (BBIO).
Which stock has performed better over the past year, BBIO or VTRS?
VTRS returned +72.49% over the past 12 months, compared with +22.65% for BBIO (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, BridgeBio Pharma or Viatris?
Viatris pays a dividend yielding 2.74%, while BridgeBio Pharma does not currently pay a regular dividend.
Are BridgeBio Pharma and Viatris in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.